JO3597B1 - توليفة من عوامل تخلُّق متوالي ومركبات ثنائية النوعية تستهدفcd33 و cd3 في علاج ابيضاض الدم النقوي - Google Patents
توليفة من عوامل تخلُّق متوالي ومركبات ثنائية النوعية تستهدفcd33 و cd3 في علاج ابيضاض الدم النقويInfo
- Publication number
- JO3597B1 JO3597B1 JOP/2014/0268A JOP20140268A JO3597B1 JO 3597 B1 JO3597 B1 JO 3597B1 JO P20140268 A JOP20140268 A JO P20140268A JO 3597 B1 JO3597 B1 JO 3597B1
- Authority
- JO
- Jordan
- Prior art keywords
- treatment
- epigenetic
- epigenetic factor
- targeting compound
- myeloid leukemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
يوفر الاختراع الحالي توليفة من عوامل التخلق المتوالي والمركبات ثنائية النوعية التي تستهدف <span dir="LTR">CD33</span> و <span dir="LTR">CD3</span> في علاج ابيضاض الدم النقوي، حيث يتم اختيار عامل التخلق المتوالي من المجموعة التي تتكون من مثبطات هستون دي أسيتيلاز (<span dir="LTR">HDAC</span>)، مثبطات ميثيل ترانسفيراز <span dir="LTR">DNA</span> (<span dir="LTR">DNMT</span>) <span dir="LTR">I</span>، هيدروكسي يوريا، عامل تحفيز مستعمرة المحببات (<span dir="LTR">G-CSF</span>)، مثبطات هستون دي ميثيلاز و <span dir="LTR">ATRA</span> (كل حمض ترانس-ريتينويك). ووفقاً لذلك، يوفر الاختراع تركيبة صيدلانية تشتمل على مركب يستهدف <span dir="LTR">CD33</span> وعامل تخلق متوالي واحد على الأقل وعامل تخلق متوالي للاستخدام في تخفيف، و/أو علاج ابيضاض الدم النقوي، وحيث يزيد عامل التخلق المتوالي من استجابية المريض للمركب المستهدف <span dir="LTR">CD33</span>. علاوة على ذلك، يوفر الاختراع استخدام عامل واحد على الأقل للتخلق المتوالي لزيادة استجابية المريض بابيضاض الدم النقوي للعلاج بالمركب الذي يستهدف <span dir="LTR">CD33</span>، طريقة علاج ابيضاض الدم النقوي، وتشتمل الطريقة على إعطاء عامل واحد على الأقل للتخلق المتوالي ومركب يستهدف <span dir="LTR">CD33</span> لمريض بحاجة إلى ذلك، وصندوق يشتمل على تركيبة صيدلانية للاختراع أو عامل تخلق متوالي للاختراع ومركب ثنائي النوعية يستهدف <span dir="LTR">CD33</span>.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361877714P | 2013-09-13 | 2013-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3597B1 true JO3597B1 (ar) | 2020-07-05 |
Family
ID=51690351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2014/0268A JO3597B1 (ar) | 2013-09-13 | 2014-09-14 | توليفة من عوامل تخلُّق متوالي ومركبات ثنائية النوعية تستهدفcd33 و cd3 في علاج ابيضاض الدم النقوي |
Country Status (28)
Country | Link |
---|---|
US (1) | US10933132B2 (ar) |
EP (1) | EP3043794B1 (ar) |
JP (1) | JP6530409B2 (ar) |
KR (1) | KR102366470B1 (ar) |
CN (2) | CN111888474A (ar) |
AP (1) | AP2016009132A0 (ar) |
AR (1) | AR097648A1 (ar) |
AU (2) | AU2014320246B2 (ar) |
CA (1) | CA2923354C (ar) |
CL (1) | CL2016000564A1 (ar) |
DK (1) | DK3043794T3 (ar) |
EA (1) | EA036476B1 (ar) |
HK (1) | HK1225975A1 (ar) |
HU (1) | HUE056867T2 (ar) |
IL (1) | IL278527B (ar) |
JO (1) | JO3597B1 (ar) |
LT (1) | LT3043794T (ar) |
MA (2) | MA46164B1 (ar) |
MX (1) | MX2016003197A (ar) |
MY (1) | MY185611A (ar) |
NZ (1) | NZ716448A (ar) |
PH (1) | PH12016500434B1 (ar) |
SG (2) | SG11201600671QA (ar) |
SI (1) | SI3043794T1 (ar) |
TW (1) | TWI688401B (ar) |
UA (1) | UA123199C2 (ar) |
WO (1) | WO2015036583A2 (ar) |
ZA (1) | ZA201600528B (ar) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
JP2018516248A (ja) | 2015-05-29 | 2018-06-21 | アンフィヴェナ セラピューティクス,インク. | 二重特異性のcd33およびcd3結合タンパク質を使用する方法 |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
SG11201804894XA (en) | 2015-12-16 | 2018-07-30 | Hoffmann La Roche | Improved recombinant production method |
JOP20170017B1 (ar) * | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
JOP20170091B1 (ar) * | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
SG11201906404RA (en) * | 2017-03-20 | 2019-08-27 | Vaccinex Inc | Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent |
KR102090407B1 (ko) * | 2017-11-24 | 2020-03-17 | 충북대학교 산학협력단 | 항-icam4 항체 및 icam4 발현 세포와 관련된 질병의 진단 및 치료용 조성물 |
WO2019103531A1 (ko) * | 2017-11-24 | 2019-05-31 | 충북대학교 산학협력단 | 항-icam4 항체 및 icam4 발현 세포와 관련된 질병의 진단 및 치료용 조성물 |
WO2019108789A1 (en) | 2017-11-29 | 2019-06-06 | The Trustees Of Columbia University In The City Of New York | Combination therapy of lymphoma |
JOP20190116A1 (ar) * | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
TW202021616A (zh) * | 2018-07-30 | 2020-06-16 | 美商安進公司 | 結合至cd33和cd3的雙特異性抗體構建體之延長投與 |
EP3849565A4 (en) | 2018-09-12 | 2022-12-28 | Fred Hutchinson Cancer Research Center | REDUCING CD33 EXPRESSION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS |
CN113045664B (zh) | 2019-11-28 | 2023-05-12 | 尚健单抗(北京)生物技术有限公司 | 一种分离的结合抗原axl的蛋白及其用途 |
CN113260704B (zh) | 2019-12-09 | 2022-06-28 | 北京中因科技有限公司 | CYP4V2和RdCVF在制备药物中的用途 |
CN112079934B (zh) | 2019-12-17 | 2021-01-29 | 合源生物科技(天津)有限公司 | 一种靶向cd19的嵌合抗原受体及其用途 |
AU2020418199B2 (en) | 2020-01-02 | 2024-06-13 | Ningbo T-Maximum Biopharmaceuticals Co., Ltd. | Modified immune effector cell and preparation method therefor |
CN113481165B (zh) * | 2020-07-16 | 2022-06-03 | 山东博安生物技术股份有限公司 | 分泌双特异性t细胞衔接子的car-t及治疗实体肿瘤的应用 |
CN111733174B (zh) | 2020-08-07 | 2021-02-09 | 北京大学第三医院(北京大学第三临床医学院) | 一种分离的核酸分子及其用途 |
TW202222840A (zh) | 2020-12-11 | 2022-06-16 | 大陸商上海華奧泰生物藥業股份有限公司 | Cd73的抗原結合蛋白及其應用 |
JP2024503425A (ja) | 2021-01-11 | 2024-01-25 | 星濟生物(蘇州)有限公司 | 黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用 |
AU2022207557A1 (en) | 2021-01-13 | 2023-07-06 | Huabo Biopharm (Shanghai) Co., Ltd. | Cd73-binding protein and use thereof |
CN112630438B (zh) * | 2021-03-08 | 2021-06-22 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | 抗体组合物及其筛查髓系疾病及检测免疫检查点的应用 |
EP4317182A1 (en) | 2021-03-22 | 2024-02-07 | Starmab Biologics (Suzhou) Co., Ltd | Antigen-binding protein targeting streptococcus pneumoniae hemolysin protein and use thereof |
WO2022206975A1 (zh) | 2021-04-02 | 2022-10-06 | 原启生物科技(上海)有限责任公司 | Cldn18.2抗原结合蛋白及其用途 |
CN113533729B (zh) * | 2021-06-15 | 2024-09-06 | 北京大学人民医院 | 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用 |
CN115612674A (zh) | 2021-07-14 | 2023-01-17 | 上海荣瑞医药科技有限公司 | 一种溶瘤病毒及其用途 |
CN113461821B (zh) * | 2021-09-03 | 2021-12-28 | 苏州近岸蛋白质科技股份有限公司 | 抗cd3人源化抗体 |
CN114540316A (zh) | 2022-01-26 | 2022-05-27 | 上海荣瑞医药科技有限公司 | 溶瘤病毒及其应用 |
CN114908087B (zh) * | 2022-05-07 | 2024-01-23 | 四川大学华西医院 | 一种长循环肾靶向细胞外囊泡的构建及其应用 |
CN118221826A (zh) * | 2024-04-25 | 2024-06-21 | 北京绿竹生物技术股份有限公司 | 一种结合人cd33和cd3的双特异性抗体 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
DK0575319T3 (da) | 1991-03-11 | 2000-07-10 | Univ Georgia Res Found | Kloning og ekspression af Renilla-luciferase |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
CA2146559A1 (en) | 1992-10-23 | 1994-05-11 | Melanie K. Spriggs | Methods of preparing soluble, oligomeric proteins |
KR960705209A (ko) | 1993-09-10 | 1996-10-09 | 잭 엠. 그랜노위츠 | 녹색 형광 단백의 용도 |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
NZ335453A (en) | 1996-12-12 | 2001-07-27 | Prolume Ltd | Microelectronic device with microlocations including photodetector for detecting bioluminescence |
DE69938293T2 (de) | 1998-03-27 | 2009-03-12 | Bruce J. Beverly Hills Bryan | Luciferase, gfp fluoreszenzproteine, kodierende nukleinsaüre und ihre verwendung in der diagnose |
DK1071752T3 (da) | 1998-04-21 | 2003-10-20 | Micromet Ag | CD19xCD3-specifikke polypeptider og anvendelsen deraf |
US20050025823A1 (en) * | 2003-07-29 | 2005-02-03 | Fong Andy A.T. | Methods of use of herbal compositions |
BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
ES2856451T3 (es) | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
AU2007317333A1 (en) * | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
RS58217B1 (sr) | 2007-04-03 | 2019-03-29 | Amgen Res Munich Gmbh | Interspecijski specifičan vezujući domen |
UA112062C2 (uk) * | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2014
- 2014-09-12 TW TW103131571A patent/TWI688401B/zh active
- 2014-09-12 AR ARP140103413A patent/AR097648A1/es unknown
- 2014-09-14 JO JOP/2014/0268A patent/JO3597B1/ar active
- 2014-09-15 UA UAA201600619A patent/UA123199C2/uk unknown
- 2014-09-15 SG SG11201600671QA patent/SG11201600671QA/en unknown
- 2014-09-15 HU HUE14783554A patent/HUE056867T2/hu unknown
- 2014-09-15 KR KR1020167008346A patent/KR102366470B1/ko active IP Right Grant
- 2014-09-15 CA CA2923354A patent/CA2923354C/en active Active
- 2014-09-15 AP AP2016009132A patent/AP2016009132A0/en unknown
- 2014-09-15 CN CN202010532460.4A patent/CN111888474A/zh active Pending
- 2014-09-15 SG SG10201801777YA patent/SG10201801777YA/en unknown
- 2014-09-15 CN CN201480061643.5A patent/CN105764505A/zh active Pending
- 2014-09-15 US US14/916,201 patent/US10933132B2/en active Active
- 2014-09-15 EP EP14783554.0A patent/EP3043794B1/en active Active
- 2014-09-15 JP JP2016542329A patent/JP6530409B2/ja active Active
- 2014-09-15 SI SI201431891T patent/SI3043794T1/sl unknown
- 2014-09-15 IL IL278527A patent/IL278527B/en unknown
- 2014-09-15 EA EA201690485A patent/EA036476B1/ru not_active IP Right Cessation
- 2014-09-15 LT LTEPPCT/EP2014/069575T patent/LT3043794T/lt unknown
- 2014-09-15 NZ NZ716448A patent/NZ716448A/en unknown
- 2014-09-15 MX MX2016003197A patent/MX2016003197A/es unknown
- 2014-09-15 DK DK14783554.0T patent/DK3043794T3/da active
- 2014-09-15 MA MA46164A patent/MA46164B1/fr unknown
- 2014-09-15 MY MYPI2016700856A patent/MY185611A/en unknown
- 2014-09-15 WO PCT/EP2014/069575 patent/WO2015036583A2/en active Application Filing
- 2014-09-15 AU AU2014320246A patent/AU2014320246B2/en active Active
-
2016
- 2016-01-25 ZA ZA2016/00528A patent/ZA201600528B/en unknown
- 2016-03-07 PH PH12016500434A patent/PH12016500434B1/en unknown
- 2016-03-09 MA MA38898A patent/MA38898A1/fr unknown
- 2016-03-10 CL CL2016000564A patent/CL2016000564A1/es unknown
- 2016-12-16 HK HK16114358A patent/HK1225975A1/zh unknown
-
2020
- 2020-04-20 AU AU2020202641A patent/AU2020202641A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3597B1 (ar) | توليفة من عوامل تخلُّق متوالي ومركبات ثنائية النوعية تستهدفcd33 و cd3 في علاج ابيضاض الدم النقوي | |
CY1121876T1 (el) | Συνθεσεις παρακαμψης εξωνιου για τη θεραπεια της μυϊκης δυστροφiας | |
PH12016500649A1 (en) | Combinations of histone deactylase inhibitors and immunomodulatory drugs | |
MX2017014299A (es) | Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. | |
BR112017000301A2 (pt) | tratamento de leucemia com inibidores de histona desacetilase | |
BR112015023001A2 (pt) | composição de salto de exon para tratamento de distrofia muscular | |
MX2020004986A (es) | Composiciones mejoradas para tratar distrofia muscular. | |
MY162146A (en) | Pharmaceutical composition | |
BR112015014987A2 (pt) | Aprimoradas composições que pulam éxon para o tratamento da distrofia muscular | |
WO2012065139A3 (en) | Entpd5 inhibitors | |
MX2014007969A (es) | Hidroxiamidas de ácido cinámico como inhibidores de la histona desacetilasa 8. | |
PH12015500069A1 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
MX365321B (es) | Métodos para el tratamiento de neutropenia mediante agonistas retinoides. | |
MX2017014300A (es) | Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. | |
PH12015502589A1 (en) | 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives | |
EP3581653A3 (en) | Methods and compositions for treating cancer using peptide nucleic acid-based agents | |
MX2016006966A (es) | Derivados de acidos grasos de inhibidores dimericos de la proteina 95 de la densidad post-sinaptica (psd-95). | |
EA201500736A1 (ru) | Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов | |
PH12016502403A1 (en) | Compositions for anti-inflammatory, antioxidant effects and improved respiratory function by specific histone deacetylase inhibition | |
EA201500737A1 (ru) | Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов | |
WO2013123081A3 (en) | Use of small molecule inhibitors targeting the interaction between rac gtpase and p67 (phox) | |
EA201491455A1 (ru) | ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
AR109858A1 (es) | Métodos que usan inhibidores hdac11 |